GT Biopharma (GTBP) EPS (Basic) (2010 - 2026)
GT Biopharma's (GTBP) quarterly EPS (Basic) came in at -$2.78 in Q1 2026, up 66.38% year-over-year from -$1.67 in Q1 2025, and up 91.84% quarter-over-quarter from -$34.08 in Q4 2025.
Powered by 
Analysis
GT Biopharma (GTBP) EPS (Basic) (2010 - 2026) Analysis & Trends
GT Biopharma (GTBP) has reported EPS (Basic) for 17 consecutive years, with -$2.78 the latest figure, recorded in Q1 2026.
- On a quarterly basis, EPS (Basic) rose 66.38% year-over-year to -$2.78 in Q1 2026; TTM through Mar 2026 was -$30.58, a 75.42% increase from a year earlier, with the FY2025 full-year figure at -$156.21, up 9.93% from the prior year.
- EPS (Basic) was -$2.78 for Q1 2026 at GT Biopharma, up from -$34.08 in the prior quarter.
- Over five years, EPS (Basic) peaked at $25.99 in Q3 2025 and troughed at -$272.88 in Q2 2025.
- A 5-year average of -$72.71 and a median of -$54.18 in 2024 frame the typical range for EPS (Basic).
- The widest YoY moves for EPS (Basic): up 168.1% in 2025, down 403.67% in 2025.
- Over 5 years, EPS (Basic) stood at -$136.0 in 2022, then surged by 59.79% to -$54.68 in 2023, then increased by 9.04% to -$49.74 in 2024, then soared by 31.48% to -$34.08 in 2025, then surged by 91.84% to -$2.78 in 2026.
- The last three EPS (Basic) figures came in at -$2.78 (Q1 2026), -$34.08 (Q4 2025), and $25.99 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 4.40 |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -8.44 |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 4.34 |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 12.62 |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 7.70 |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -1.96 |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 1.23 |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 0.66 |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -0.06 |
| 10 | GT Biopharma | 337,746.23 | 337,746.23 | - | -2.78 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -2.78 |
| Dec 31, 2025 | -34.08 |
| Sep 30, 2025 | 25.99 |
| Jun 30, 2025 | -272.88 |
| Mar 31, 2025 | -8.27 |
| Dec 31, 2024 | -49.74 |
| Sep 30, 2024 | -38.17 |
| Jun 30, 2024 | -54.18 |
| Mar 31, 2024 | -53.40 |
| Dec 31, 2023 | -54.68 |
| Sep 30, 2023 | -53.14 |
| Jun 30, 2023 | -67.63 |
| Mar 31, 2023 | -71.25 |
| Dec 31, 2022 | -136.00 |
| Sep 30, 2022 | -167.87 |
| Jun 30, 2022 | -72.37 |
| Mar 31, 2022 | -125.65 |
| Dec 31, 2021 | -484.70 |
| Sep 30, 2021 | -141.55 |
| Jun 30, 2021 | -108.79 |